Did you read this link? The abstract says that weight loss drugs have been used to... "improve glycemic control and cardiovascular outcomes among people with type 2 diabetes and a high cardiovascular risk"
BUT to identify patients with heart failure (which is a serious medical condition - my 83 year old dad died of it last year) they suggest performing screening and then, IF the patient has heart failure and IF they have a reduced ejection fraction (which is the heart not pushing out as much blood when it contracts), you should be cautious of using weight loss drugs as there have been many studies on how the drugs might affect their existing illness and could make it worse.
So for most people the drugs improve cardiovascular outcomes. For a small number of people already sick the need to be cautious is there isn't enough studies done yet and it MIGHT be a problem.
Full abstract text:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RAs may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across a patient's risk with a particular focus on HF. After a careful review of the literature, we challenge the current views about the use of GLP-1 RAs and suggest performing active HF screening (with directed clinical history, physical examination, an echocardiogram, and natriuretic peptides) before initiating a GLP-1 RA. After HF screening, we suggest GLP-1 RA treatment decisions as follows: (1) in people with T2D without HF, GLP-1 RAs should be used for reducing the risk of myocardial infarction and stroke, with a possible effect to reduce the risk of HF hospitalizations; (2) in patients with HF and preserved ejection fraction, GLP-1 RAs do not reduce HF hospitalizations but may reduce atherosclerotic events, and their use may be considered in an individualized manner; and (3) in patients with HF and reduced ejection fraction, the use of GLP-1 RAs warrants caution due to potential risk of worsening HF events and arrhythmias, pending risk-benefit data from further studies.